Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Y-mAbs Therapeutics, Inc. (YMAB : NSDQ)

• Company Description    Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. Number of Employees: 107

• Price / Volume Information    Yesterday's Closing Price: $4.30 Daily Weekly Monthly 20 Day Moving Average: 197,003 shares Shares Outstanding: 45.28 (millions) Market Capitalization: $194.72 (millions) Beta: 0.51 52 Week High: $16.11 52 Week Low: $3.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.69% -20.25% 12 Week -1.15% -17.07% Year To Date -45.08% -48.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 202 Carnegie Center Suite 301 - PRINCETON,NJ 08540 USA ph: 646-885-8505 fax: - cdu@ymabs.com http://www.ymabs.com

• General Corporate Information    Officers Michael Rossi - Chief Executive Officer;President and Director Peter Pfreundschuh - Chief Financial Officer and Treasurer Thomas Gad - Director Johan Wedell-Wedellsborg - Director Laura J. Hamill - Director Peer Information Y-mAbs Therapeutics, Inc. (CORR.) Y-mAbs Therapeutics, Inc. (RSPI) Y-mAbs Therapeutics, Inc. (CGXP) Y-mAbs Therapeutics, Inc. (BGEN) Y-mAbs Therapeutics, Inc. (GTBP) Y-mAbs Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 984241109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 45.28 Most Recent Split Date: (:1) Beta: 0.51 Market Capitalization: $194.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.97 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 43.63% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.18 Price/Cash Flow: - Price / Sales: 2.20 EPS Growth vs. Year Ago Period: 20.00% vs. Previous Quarter: 20.00% Sales Growth vs. Year Ago Period: 4.88% vs. Previous Quarter: -21.10% ROE 06/30/25 - - 03/31/25 - -30.59 12/31/24 - -31.31 ROA 06/30/25 - - 03/31/25 - -22.70 12/31/24 - -23.35 Current Ratio 06/30/25 - - 03/31/25 - 4.77 12/31/24 - 4.16 Quick Ratio 06/30/25 - - 03/31/25 - 4.35 12/31/24 - 3.85 Operating Margin 06/30/25 - - 03/31/25 - -31.84 12/31/24 - -33.83 Net Margin 06/30/25 - - 03/31/25 - -31.84 12/31/24 - -33.83 Pre-Tax Margin 06/30/25 - - 03/31/25 - -32.18 12/31/24 - -34.00 Book Value 06/30/25 - - 03/31/25 - 1.98 12/31/24 - 2.05 Inventory Turnover 06/30/25 - - 03/31/25 - 1.91 12/31/24 - 1.78 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©